| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2017118822 |
| Title |
Multi-Target Compounds with Inhibitory Activity Towards Histone Deacetylases and Tubulin Polymerisation, for Use In The Treatment of Cancer. |
| Abstract |
The present invention relates to the design of new molecules, referred to as ...ulti-target...molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDAC) and as inhibitors of tubulin polymerisation. The invention also describes the method for synthesising the ...ulti-target...molecules and their use in the treatment of cancer, a pharmaceutical composition comprising at least one ...ulti-target...molecule, and the use of such compositions in the treatment of cancer. |
| Applicant(s) |
Center National De La Recherche Scientifique (Cnrs) |
| Representative Drug(s) |
D04JWR |
Drug Info
|
IC50 = 110 nM |
[1] |
| Patent ID |
WO2015175813 |
| Title |
Heterocyclic Hydroxamic Acids As Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof. |
| Abstract |
The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mpsl kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mpsl kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation. |
| Applicant(s) |
The Regents of the University of Colorado, A Body Corporate |
| Representative Drug(s) |
D0BP8I |
Drug Info
|
IC50 = 12 nM |
[1] |
| Patent ID |
WO2014178606 |
| Title |
Novel Compounds for Selective Histone Deacetylase Inhibitors, and Pharmaceutical Composition Comprising The Same. |
| Abstract |
The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (HDAC) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc. |
| Applicant(s) |
Chong Kun Dang Pharmaceutical Corp |
| Representative Drug(s) |
D0LP1K |
Drug Info
|
IC50 = 8420 nM |
[1] |
| Patent ID |
WO2014122222 |
| Title |
Hydroxamate Derivatives Bearing Amide-Lactams As Potent Hdac Inhibitors and Their Uses As Medicaments. |
| Abstract |
The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds. |
| Applicant(s) |
Sigma-Tau Industrie Farmaceutiche Riunite Spa |
| Representative Drug(s) |
D0N2DK |
Drug Info
|
IC50 < 150 nM |
[1] |
| Patent ID |
WO2013041480 |
| Title |
New Thio Derivatives Bearing Lactams As Potent Hdac Inhibitors and Their Uses As Medicaments. |
| Abstract |
The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds. |
| Applicant(s) |
Sigma-Tau Industrie Farmaceutiche Riunite Spa |
| Representative Drug(s) |
D07WAT |
Drug Info
|
IC50 = 100 to 500 nM |
[1] |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US20170044185 |
| Title |
Preparation of Histone Deacetylase (Hdac) Inhibitors and Methods for Use Thereof. |
| Representative Drug(s) |
D0RA0D |
Drug Info
|
IC50 = 2840 nM |
[1] |
